In addition, in an in vivo setting birabresib induced synthetic lethality via restoring loss of MYC repression in SMAD4-deficient CRC cells, confirming the data from McCleland and colleagues about the feasibility of treating MYC-overexpressing tumors with BET-i. The gene discussed is MYC; the disease is colorectal carcinoma.